Kolexia
Nancey Stephane
Gastro-entérologie
Hôpital Lyon Sud
Pierre-Bénite, France
390 Activités
364 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie de Crohn Maladies inflammatoires intestinales Rectocolite hémorragique Colite Nécrose Ulcère Inflammation Abcès Syndrome du côlon irritable

Industries

B3TSI
110 collaboration(s)
Dernière en 2023
M3 Global Research Ltd
102 collaboration(s)
Dernière en 2023
Janssen
80 collaboration(s)
Dernière en 2023
A+A
62 collaboration(s)
Dernière en 2023

Dernières activités

LUCENT-URGE: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Essai Clinique (Lilly)   07 mars 2024
Peptide-Based Hydrogel for Nanosystems Encapsulation: the Next Generation of Localized Delivery Systems for the Treatment of Intestinal Inflammations.
Advanced healthcare materials   06 mars 2024
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional Study.
Inflammatory bowel diseases   08 février 2024
TOPIC: TOward a Better Understanding of the autoPhagy Machinery for the Identification of Potential Novel Biomarkers and Therapeutic Targets in Crohn's Disease - TOPIC Study
Essai Clinique (Hospices Civils de Lyon)   29 janvier 2024
USTAP: USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Essai Clinique (Janssen)   18 janvier 2024
TRENCH 1: TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study
Essai Clinique (Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives)   15 janvier 2024
ABTECT - Maintenance: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   07 décembre 2023
What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?
Journal of clinical medicine   04 décembre 2023